Court awards claimant $13.5m in rofecoxib lawsuitBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7547.927-a (Published 20 April 2006) Cite this as: BMJ 2006;332:927
- Janice Hopkins Tanne
- New York
A jury in New Jersey has awarded $4.5m (£2.6m; €3.7m) in compensatory damages to a 77 year old man who claimed that rofecoxib (Vioxx) had caused his heart attack. The jury decided that Merck, the maker of the cyclo-oxygenase-2 inhibitor, had deceived the US Food and Drug Administration about the safety of the drug and awarded the man an additional $9m in punitive damages.
Merck said it had given the FDA all the necessary information about rofecoxib and would appeal the ruling.
The jury decided that the heart attack …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial